Schellenberg, R. (2001). Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ (Clinical Research Ed.), 322(7279), 134-137. https://doi.org/10.1136/bmj.322.7279.134
Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001;322(7279):134-137. doi:10.1136/bmj.322.7279.134
Schellenberg, R. "Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study." BMJ (Clinical Research Ed.), vol. 322, no. 7279, 2001, pp. 134-137.
Agnus castus extract improved premenstrual symptoms more than placebo
Women taking agnus castus extract improved more than women taking placebo over three cycles, a randomized, double-blind trial of 170 women with premenstrual syndrome found. A 50% symptom reduction defined a responder. Responders numbered 52 out of 100 on agnus castus and 24 out of 100 on placebo.
Study at a glance, randomized, double-blind trial of 170 women with premenstrual syndrome: Agnus castus improved premenstrual symptoms more than placebo. Source: Schellenberg R, 2001, PMID 11159568.
Key Findings
The combined six-item symptom score fell by 128.5 mm on agnus castus and 78.1 mm on placebo, a difference in mean reduction of 50.5 mm (95% CI 23.5 to 77.5).
Five of the six self-rated symptoms improved more on agnus castus: irritability, mood alteration, anger, headache and breast fullness. Other symptoms including bloating showed no significant difference.
Physicians' clinical global impression ratings of severity, global improvement and overall assessment of risk or benefit each showed significant superiority of agnus castus.
The responder rate, a 50% reduction in symptoms, was 52% on agnus castus and 24% on placebo.
Seven women reported mild adverse events (four on agnus castus, three on placebo), and none of these events led to stopping treatment.
Interpretation
The trial randomized women to an extract tablet or a matching placebo, with neither women nor clinicians told which. Researchers studied 170 women (86 on agnus castus, 84 on placebo) with premenstrual syndrome, treated for three cycles at six clinics. The main outcome was the women's own symptom ratings, and physician ratings agreed. Excluding women on oral contraceptives did not change the results. The tested product was one extract, Ze 440. The authors note they have no data on symptoms after treatment stopped, though other researchers found the effects last up to three cycles afterward. The findings support larger studies of this herbal treatment.
RRM Context
The trial required symptoms in the week before bleeding, easing after the follicular phase began. This ties premenstrual syndrome to the timing of the cycle. Restorative reproductive medicine reads such symptoms against that timing. The authors call agnus castus a good option when the cause of the syndrome cannot be found.
Our editorial summary of this paper, not the article's abstract.
Abstract
Objectives
To compare the efficacy and tolerability of agnus castus fruit (Vitex agnus castus L extract Ze 440) with placebo for women with the premenstrual syndrome.
Design
Randomised, double blind, placebo controlled, parallel group comparison over three menstrual cycles.
Setting
General medicine community clinics.
Participants
178 women were screened and 170 were evaluated (active 86; placebo 84). Mean age was 36 years, mean cycle length was 28 days, mean duration of menses was 4.5 days.
Interventions
Agnus castus (dry extract tablets) one tablet daily or matching placebo, given for three consecutive cycles.
Main Outcome Measures
Main efficacy variable: change from baseline to end point (end of third cycle) in women's self assessment of irritability, mood alteration, anger, headache, breast fullness, and other menstrual symptoms including bloating. Secondary efficacy variables: changes in clinical global impression (severity of condition, global improvement, and risk or benefit) and responder rate (50% reduction in symptoms).
Results
Improvement in the main variable was greater in the active group compared with placebo group (P<0.001). Analysis of the secondary variables showed significant (P<0.001) superiority of active treatment in each of the three global impression items. Responder rates were 52% and 24% for active and placebo, respectively. Seven women reported mild adverse events (four active; three placebo), none of which caused discontinuation of treatment.
Conclusions
Dry extract of agnus castus fruit is an effective and well tolerated treatment for the relief of symptoms of the premenstrual syndrome.